|
Market Cap | 213.88M | EPS (ttm) | -1.08 |
P/E | - | EPS this Y | -8.54% |
Forward P/E | - | EPS next Y | -19.34% |
PEG | - | EPS past 5Y | -54.03% |
P/S | - | EPS next 5Y | 22.89% |
P/B | 0.77 | EPS Q/Q | 9.53% |
Dividend | - | Sales Q/Q | - |
Insider Own | 26.14% | Inst Own | 55.52% |
Insider Trans | -0.22% | Inst Trans | 4.20% |
Short Float | 2.09% | Earnings | May 14/b |
Analyst Recom | 1.00 | Target Price | 13.50 |
Avg Volume | 317.55K | 52W Range | 1.81 - 11.31 |
|
|
|
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
OConnell Daniel Joseph | President and CEO | Jan 19 '24 | Sale | 3.47 | 15,200 | 52,753 | 502,485 | Jan 19 07:07 PM | Meisner Derek M | Chief Legal Officer & Corp Sec | Jan 19 '24 | Sale | 3.48 | 8,933 | 31,048 | 108,867 | Jan 19 07:06 PM | Zuga Matt | CFO & Chief Business Officer | Jan 18 '24 | Sale | 3.71 | 4,242 | 15,717 | 211,445 | Jan 19 07:05 PM | Siemers Eric | Chief Medical Officer | Jan 18 '24 | Sale | 3.71 | 3,124 | 11,604 | 117,576 | Jan 19 07:05 PM | Barton Russell | Chief Operating Officer | Jan 18 '24 | Sale | 3.73 | 2,833 | 10,555 | 96,867 | Jan 19 07:04 PM |
|
|
|
|
Market Cap | 557.87M | EPS (ttm) | -1.20 |
P/E | - | EPS this Y | 29.72% |
Forward P/E | - | EPS next Y | 9.29% |
PEG | - | EPS past 5Y | -46.78% |
P/S | 97.53 | EPS next 5Y | 23.30% |
P/B | 2.61 | EPS Q/Q | -19.28% |
Dividend | - | Sales Q/Q | -78.29% |
Insider Own | 21.16% | Inst Own | 34.81% |
Insider Trans | 0.94% | Inst Trans | 3.16% |
Short Float | 9.06% | Earnings | May 14/b |
Analyst Recom | 1.33 | Target Price | 8.60 |
Avg Volume | 1.39M | 52W Range | 1.11 - 6.72 |
|
|
|
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Redmile Group, LLC | Director | Mar 01 '24 | Buy | 4.50 | 222,222 | 999,999 | 8,253,316 | Mar 05 09:30 PM |
|
|
|
|
Market Cap | 263.87M | EPS (ttm) | -2.73 |
P/E | - | EPS this Y | -1.79% |
Forward P/E | - | EPS next Y | 1.10% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 1.59 | EPS Q/Q | -101.64% |
Dividend | - | Sales Q/Q | - |
Insider Own | 32.95% | Inst Own | 62.80% |
Insider Trans | 30.08% | Inst Trans | - |
Short Float | 5.24% | Earnings | May 14/b |
Analyst Recom | 1.20 | Target Price | 21.22 |
Avg Volume | 791.15K | 52W Range | 3.19 - 14.30 |
|
|
|
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
PERCEPTIVE ADVISORS LLC | 10% Owner | Apr 11 '24 | Buy | 8.50 | 2,353,000 | 20,000,500 | 5,360,858 | Apr 15 08:53 AM | Chione Ltd | 10% Owner | Jun 26 '23 | Sale | 12.93 | 16 | 207 | 3,848,632 | Jun 28 03:47 PM | Holm-Jorgensen Rasmus | Chief Financial Officer | Jun 16 '23 | Option Exercise | 3.63 | 9,500 | 34,485 | 29,530 | Jun 20 05:21 PM | Chione Ltd | 10% Owner | Jun 15 '23 | Sale | 12.14 | 2,056 | 24,960 | 3,848,648 | Jun 20 05:15 PM | Chione Ltd | 10% Owner | Jun 14 '23 | Sale | 12.13 | 893 | 10,832 | 3,850,704 | Jun 14 06:33 PM |
|
|
| |
|
Market Cap | 171.77M | EPS (ttm) | -2.16 |
P/E | - | EPS this Y | 98.73% |
Forward P/E | 16.00 | EPS next Y | 2150.00% |
PEG | - | EPS past 5Y | 21.42% |
P/S | 2.13 | EPS next 5Y | - |
P/B | 3.72 | EPS Q/Q | 87.13% |
Dividend | - | Sales Q/Q | 87.51% |
Insider Own | 9.92% | Inst Own | 93.09% |
Insider Trans | 0.00% | Inst Trans | 0.45% |
Short Float | 0.26% | Earnings | May 14/b |
Analyst Recom | 1.00 | Target Price | 8.00 |
Avg Volume | 75.75K | 52W Range | 1.64 - 4.38 |
|
|
|
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Caligan Partners LP | 10% Owner | Sep 14 '23 | Buy | 3.39 | 579,000 | 1,962,810 | 16,835,154 | Sep 15 04:05 PM | Caligan Partners LP | 10% Owner | Sep 14 '23 | Sale | 3.39 | 579,000 | 1,962,810 | 16,256,154 | Sep 15 04:05 PM | Morgan Adam | Director | May 17 '23 | Buy | 1.70 | 1,401,901 | 2,383,232 | 1,659,654 | May 19 05:17 PM |
|
|
|
|
Market Cap | 88.65M | EPS (ttm) | -4.34 |
P/E | - | EPS this Y | 62.58% |
Forward P/E | - | EPS next Y | 44.87% |
PEG | - | EPS past 5Y | - |
P/S | 2.25 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -3253.12% |
Dividend | - | Sales Q/Q | - |
Insider Own | 24.13% | Inst Own | 19.07% |
Insider Trans | 0.00% | Inst Trans | -8.35% |
Short Float | 1.45% | Earnings | May 14/b |
Analyst Recom | 1.00 | Target Price | 5.00 |
Avg Volume | 1.04M | 52W Range | 1.56 - 10.94 |
|
|
|
Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Chardon Benoit | Chief Commercial Officer | Dec 12 '23 | Option Exercise | 1.19 | 165,539 | 197,562 | 199,183 | Dec 14 07:17 PM |
|
|
| |
|
Market Cap | 32.04M | EPS (ttm) | -4.00 |
P/E | - | EPS this Y | 34.26% |
Forward P/E | - | EPS next Y | 41.21% |
PEG | - | EPS past 5Y | 23.41% |
P/S | 55.24 | EPS next 5Y | - |
P/B | 1.30 | EPS Q/Q | 94.99% |
Dividend | - | Sales Q/Q | - |
Insider Own | 11.91% | Inst Own | 18.84% |
Insider Trans | 2.66% | Inst Trans | -45.51% |
Short Float | 1.90% | Earnings | May 14/b |
Analyst Recom | 1.00 | Target Price | 15.67 |
Avg Volume | 30.73K | 52W Range | 2.78 - 8.85 |
|
|
|
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Seizinger Bernd R. | Director | Mar 13 '24 | Buy | 7.29 | 6,860 | 50,009 | 33,685 | Mar 14 08:53 PM | HENNEMAN JOHN B III | Director | Mar 13 '24 | Buy | 7.29 | 6,860 | 50,009 | 8,139 | Mar 14 08:52 PM | Gilad Oren | President, CEO | Mar 13 '24 | Buy | 7.29 | 2,000 | 14,580 | 324,770 | Mar 14 08:51 PM | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Mar 13 '24 | Buy | 7.29 | 1,010 | 7,363 | 15,503 | Mar 14 08:54 PM | Seizinger Bernd R. | Director | Jun 07 '23 | Buy | 3.68 | 6,029 | 22,192 | 26,325 | Jun 08 04:34 PM |
|
|
|
|
Market Cap | 48.42M | EPS (ttm) | -1.76 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 0.26 | EPS next 5Y | - |
P/B | 0.94 | EPS Q/Q | -20.22% |
Dividend | 5.58% | Sales Q/Q | 0.09% |
Insider Own | 50.45% | Inst Own | 17.20% |
Insider Trans | 0.00% | Inst Trans | 7.03% |
Short Float | 0.91% | Earnings | May 14/b |
Analyst Recom | - | Target Price | - |
Avg Volume | 2.38K | 52W Range | 10.27 - 18.75 |
|
|
|
Ark Restaurants Corp. engages in the operation of restaurants and bars, fast food concepts, and catering operations. It operates in New York City, Florida, Washington, D.C, Las Vegas, NV, and the gulf coast of Alabama. The company was founded on January 4, 1983 and is headquartered in New York, NY. |
|
| |
|
Market Cap | 7.32M | EPS (ttm) | -1.16 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -120.57% |
P/S | 0.61 | EPS next 5Y | - |
P/B | 1.38 | EPS Q/Q | 84.62% |
Dividend | - | Sales Q/Q | -93.46% |
Insider Own | 13.40% | Inst Own | 2.76% |
Insider Trans | 0.00% | Inst Trans | -9.88% |
Short Float | 13.07% | Earnings | May 14/b |
Analyst Recom | 1.00 | Target Price | 3.10 |
Avg Volume | 444.29K | 52W Range | 0.26 - 4.95 |
|
|
|
Golden Minerals Co. engages in the exploration of gold and silver resource properties. It focuses on a portfolio of precious metals projects which include Velardena Properties and the Rodeo gold project in Durango State, Mexico, the El Quevar silver project in Salta province of Argentina, the Yoquivo gold-silver district-scale project in Chihuahua, Mexico, the Sand Canyon gold-silver project in northwestern Nevada, and additional traditional silver-producing projects in Mexico. The company was founded in 1996 and is headquartered in Golden, CO. |
|
|
|
Market Cap | 698.05M | EPS (ttm) | -1.20 |
P/E | - | EPS this Y | 42.59% |
Forward P/E | - | EPS next Y | 17.38% |
PEG | - | EPS past 5Y | 3.32% |
P/S | 410.62 | EPS next 5Y | - |
P/B | 6.26 | EPS Q/Q | -92.78% |
Dividend | - | Sales Q/Q | -100.00% |
Insider Own | 9.38% | Inst Own | 63.69% |
Insider Trans | 0.00% | Inst Trans | -1.84% |
Short Float | 2.23% | Earnings | May 14/b |
Analyst Recom | 1.36 | Target Price | 10.69 |
Avg Volume | 1.60M | 52W Range | 2.01 - 7.45 |
|
|
|
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom. |
|
|
|
Market Cap | 189.36B | EPS (ttm) | 5.49 |
P/E | 14.40 | EPS this Y | -5.03% |
Forward P/E | 8.50 | EPS next Y | 13.92% |
PEG | 1.42 | EPS past 5Y | 1.29% |
P/S | 1.45 | EPS next 5Y | 10.11% |
P/B | 1.39 | EPS Q/Q | -68.77% |
Dividend | 1.05% | Sales Q/Q | 3.45% |
Insider Own | 0.22% | Inst Own | 14.15% |
Insider Trans | 0.00% | Inst Trans | -10.92% |
Short Float | 1.84% | Earnings | May 14/b |
Analyst Recom | 1.52 | Target Price | 102.97 |
Avg Volume | 14.58M | 52W Range | 66.63 - 102.50 |
|
|
|
Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China. |
|
|